drugset / Trial / NCT02106975

Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury

NCT02106975

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Hypothesis 1A: Vitamin C infusion will significantly attenuate sepsis-induced systemic organ failure as measured by Sequential Organ Failure Assessment (SOFA) score, Hypothesis 1B: Vitamin C infusion will attenuate sepsis-induced lung injury as assessed by the oxygenation index and the VE40 Hypothesis 1C: Vitamin C infusion will attenuate biomarkers of inflammation (C-Reactive Protein, Procalcitonin), vascular injury (Thrombomodulin, Angiopoietin-2), alveolar epithelial injury (Receptor for Advanced Glycation Products), while inducing the onset of a fibrinolytic state (Tissue Factor Pathway Inhibitor).

Timeline

Start
2014-04
Primary completion
2017-11-16
Completion
2018-01-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Vitamin C Other / unclassified 50 mg/kg Intravenous